Literature DB >> 18596431

Prospective staged volume radiosurgery for large arteriovenous malformations: indications and outcomes in otherwise untreatable patients.

Sait Sirin1, Douglas Kondziolka, Ajay Niranjan, John C Flickinger, Ann H Maitz, L Dade Lunsford.   

Abstract

OBJECTIVE: The obliteration response of an arteriovenous malformation (AVM) to radiosurgery is strongly dependent on dose and volume. For larger volumes, the dose must be reduced for safety, but this compromises obliteration. In 1992, we prospectively began to stage anatomic components in order to deliver higher single doses to symptomatic AVMs > 15 ml in volume.
METHODS: During a 17-year interval at the University of Pittsburgh, 1040 patients underwent radiosurgery for a brain AVM. Out of 135 patients who had multiple procedures, 37 patients underwent prospectively staged volume radiosurgery for symptomatic otherwise unmanageable larger malformations. Twenty-eight patients who were managed before 2002 were included in this study to achieve sufficient follow-up in assessing the outcomes. The median age was 37 years (range, 13-57 yr). Thirteen patients had previous hemorrhages and 13 patients had attempted embolization. Separate anatomic volumes were irradiated at 3 to 8 months (median, 5 mo) intervals. The median initial AVM volume was 24.9 ml (range, 10.2-57.7 ml). Twenty-six patients had two stages and two had three-stage radiosurgery. Seven patients had repeat radiosurgery after a median interval of 63 months. The median target volume was 12.3 ml. (range, 4.2-20.8 ml.) at Stage I and 11.5 ml. (range, 2.8-22 ml.) at Stage II. The median margin dose was 16 Gy at both stages. Median follow-up after the last stage of radiosurgery was 50 months (range, 3-159 mo).
RESULTS: Four patients (14%) sustained a hemorrhage after radiosurgery; two died and two patients recovered with mild permanent neurological deficits. Worsened neurological deficits developed in one patient. Seizure control was improved in three patients, was stable in eight patients and worsened in two. Magnetic resonance imaging showed T2 prolongation in four patients (14%). Out of 28 patients, 21 had follow-up more than 36 months. Out of 21 patients, seven underwent repeat radiosurgery and none of them had enough follow- up. Of 14 patients followed for more than 36 months, seven (50%) had total, four (29%) near total, and three (21%) had moderate AVM obliteration.
CONCLUSIONS: Prospective staged volume radiosurgery provided imaging defined volumetric reduction or closure in a series of large AVMs unsuitable for any other therapy. After 5 years, this early experience suggests that AVM related symptoms can be stabilized and anticipated bleed rates can be reduced.

Entities:  

Year:  2008        PMID: 18596431     DOI: 10.1227/01.neu.0000316278.14748.87

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

Review 1.  The role of microsurgical resection and radiosurgery for cerebral arteriovenous malformations.

Authors:  Joseph Serrone; Mario Zuccarello
Journal:  Methodist Debakey Cardiovasc J       Date:  2014 Oct-Dec

2.  Radiosurgical considerations in the treatment of large cerebral arteriovenous malformations.

Authors:  Sung Ho Lee; Young Jin Lim; Seok Keun Choi; Tae Sung Kim; Bong Arm Rhee
Journal:  J Korean Neurosurg Soc       Date:  2009-10-31

3.  Embolization and radiosurgery for arteriovenous malformations.

Authors:  Andres R Plasencia; Alejandro Santillan
Journal:  Surg Neurol Int       Date:  2012-04-26

4.  Quantification of hemodynamics of cerebral arteriovenous malformations after stereotactic radiosurgery using 4D flow magnetic resonance imaging.

Authors:  Shanmukha Srinivas; Tara Retson; Aaron Simon; Jona Hattangadi-Gluth; Albert Hsiao; Nikdokht Farid
Journal:  J Magn Reson Imaging       Date:  2020-12-22       Impact factor: 5.119

5.  Combined Microsurgery and Endovascular Intervention in One-Stop for Treatment of Cerebral Arteriovenous Malformation: The Efficacy of a Hybrid Operation.

Authors:  Jun Wen; Jie Lu; Xiaojun Wu; Fanfan Chen; Ning Li; Hua He; Xiangyu Wang
Journal:  Cell Transplant       Date:  2019-04-24       Impact factor: 4.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.